SlideShare a Scribd company logo
Predictors and Outcomes
 of Pneumonia in Patients
        With Spontaneous
Intracerebral Hemorrhage

                     Alsumrain M, et al
                 J Intensive Care Med
                     February 14, 2012




                        Journal Reading
                       Ersifa Fatimah, dr.
     Pembimbing: dr. Hendro Susilo, SpS(K)
       Pengamat: dr. Yudha Haryono, SpS
Introduction
ICH, common form of stroke  1/5 of all cases


Respiratory tract infection in ICU 30-60% of all infection

Pneumonia have the highest mortality rate among all
medical complications after stroke

To predict which patients will benefit from early & more
aggressive treatment

There is little data on the incidence of pneumonia in patients
with ICH / neuro-ICU
                                                                 2
Objectives
To determine the
predictors and
outcomes of the
development of
pneumonia in patients
with sICH.
                        3
Methods
290 consecutive patients with sICH admitted within 24 hours of stroke onset, at New
Jersey Neuroscience Institute - J F Kennedy Hospital, from January 2006 to July 2009




                                       Data

 Demographic data                  GCS & mRS               Pneumonia & exposure



                                 Additional data

      Site & type pneumonia, LoS, PPI, H2B, ACE-I, smoking, alcohol




                                Statistical analysis


                                                                                       4
Definitions
Pneumonia

• Dx: 2007 consensus guidelines from the Infectious Diseases Society of
  America & the American Thoracic Society
• Include: a constellation of suggestive clinical features, a
  demonstrable infiltrate by chest radiograph or other imaging
  technique, with / without supporting microbiological data.

Ventilator-associated pneumonia (VAP)

• Exposure to MV at any point during hospital course
• Px developed pneumonia after 48 hours on the ventilator
• Uses VAP bundle according to the Joint Commission on
  Accreditation of Healthcare Organizations for the prevention of
  pneumonia in mechanically ventilated patients.

Dysphagia

• diagnosed after a standardized speech and swallow evaluation
  completed by a team of speech therapist.

Tube feeding

• Started within 48 hours of hospitalization.
                                                                           5
Results & Discussion




•   290 patients (-10?)
•   159 (56.5%) male
•   mean age of 66.6 years (SD +/- 16.2).
•   13.93% patients developed pneumonia.

                                            6
Cont.




•   Patients who developed pneumonia had a lower GCS (mean = 9.1) &
    higher mRS (mean = 4) on admission. Those without pneumonia, the mean
    of GCS = 12.6 & mRS = 2.77


Substantial risk of pneumonia is associated with
(each of these parameters, cut offs):
mRS 2.5 (=< 2 vs =>3)                ORa 5.18 (2.10 – 12.8)
GCS 13.5 (=<13 vs =>14)              ORa 6.27 (2.84 – 13.9)
                                                                      7
PPI , H2-blockers and Pneumonia

 Normal gastric juice with a pH below 4  most
 pathogens are killed

 • Suppression of gastric acid  no defense from bacteria
   multiplying  colonization of pathogens, particularly gram-
   positive bacteria, from the upper GIT
 • Aspiration is important mechanism in the development of
   nosocomial pneumonia.

 Degree of bacterial overgrowth depends on
 the degree of reduction in gastric acid
 secretion

 • Bacterial overgrowth is considerably higher in patients
   treated with PPI compared with H2-receptor antagonist.


                                                                 8
ACE inhibitors & Pneumonia
Our study                             Other studies
The use of ACE-I predisposes those    ACE-I beneficial for elderly patients
with sICH to develop pneumonia        with intracerebral hemorrhage or
                                      stroke, who are at risk of
                                      pneumonia.


Protective effects of ACE-I

 • Attributed to an increase in substance P & bradykinin.


ACE-I has different effects on racial populations:

 • Most of the studies involving ACE-I involve only Asian population.
 • Studies involving a general white population show no reduced
   hospitalization for community acquired pneumonia for patients using
   ACE-I.
                                                                          9
•   93(33.2%)patients required mechanical ventilation at one point of
    their disease course  VAP 76%.
•   The most common site of pneumonia: the right lower lobe (41%).
•   The most common isolated organisms: Pseudomonas aeruginosa &
    Klebsiella pneumoniae, from 12 patients (30.7%) with pneumonia


Univariate analysis:     Variables & OR (95% CI)
Mechanical ventilation               9.42 (4.24 - 20.9)
Tube feeding                         22.3 (8.91 – 55.8)
Dysphagia                            13.1 (4.66 – 36.7)
Tracheostomy                         26.8 (8.02 – 89.3)
                                                                        10
Multivariate analysis   • Relatively small
                          differences in ORa
                          after adjusting for
                          potential
                          confounders
                        • Most interaction
                          terms were not
                          significant
                        • Exception:
                            o   H2-blockers for MV
                            o   GCS & mRS for all but
                                dysphagia & MV [only
                                GCS yielded a
                                significant interaction].


                        All potential
                        confounders left the 4
                        primary exposures
                        statistically significant
                        after adjustment.


                                                     11
• Primary route of
                                                   bacterial entry into
                                                   the trachea:
                                                     •   aspiration of
                                                         oropharyngeal
                                                         pathogens
                                                     •   leakage of
                                                         bacteria around
                                                         the endotracheal
                                                         tube cuff.
                                               • Frequent need of
                                                 MV in px with sICH
                                                  at a higher risk of
                                                 pneumonia than
                                                 any other group of
                                                 patients. (in this
                                                 study, 76.9% of
                                                 patients who
                                                 developed
The minimum ORa was 3.72 (95% CI: 1.68 - 8.26)   pneumonia were on
when adjusted for GCS                            MV)

                                                                       12
•   The bronchial
                                                   colonization of
                                                   bacteria in upper
                                                   airways during
                                                   tracheostomy 
                                                   reservoir for the
                                                   lower airways
                                                   colonization 
                                                   increases risk of
                                                   pneumonia.
                                               •   Subsequent need
                                                   for tracheostomy
                                                   who required
                                                   prolonged use of
                                                   MV  with
                                                   tracheostomy, incre
                                                   ased risk of
mRS reduced OR to 16.2 (95% CI: 4.98 - 52.8)       ventilator-
for tracheostomy                                   associated
                                                   tracheobronchitis ~
                                                   precursor for VAP.
                                                                   13
The mechanisms
                                     responsible:
                                     •   desensitization of the
                                         pharyngo-glottal
                                         adduction reflex,
                                     •   loss of anatomical
                                         integrity of the
                                         esophageal
                                         sphincters,
                                     •   migration of gastric
                                         bacteria upward
                                         along the tube
                                         causing colonization
                                         of the pharynx.




• Both GCS and mRS reduced ORa
• GCS  to14.7(95% CI: 6.16-35.0)
• mRS  to15.7(95% CI: 6.63-37.0).

                                                             14
• Dysphagia is seen in
                                           40 - 70% of patients
                                           who had an acute
                                           stroke  40 - 50%
                                           aspirate  increases
                                           the likelihood of
                                           developing
                                           pneumonia by 7-fold.




mRS reduced OR to 7.46 (95% CI: 3.34 -
10.6)



                                                              15
Effect of pneumonia on morbidity:
• Increase in mRS between admission and discharge:
   o by 1.07(4-5.07) in patients with pneumonia
   o by 0.33 (2.77-3.1) in patients without pneumonia
   o P = .003

• The hospital length of stay:
   o The pneumonia group (mean = 19.56 days)
   o The no-pneumonia group (mean = 9.14 days),
   o P <.0001.

• Mortality rate:
   o 10 (25.6%) patients died in pneumonia group
   o 30 (12%)patients died in no pneumonia group
   o P = .041



                                                        16
Limitations
• Retrospective protocol:
  o Some limitations, primarily due to existing documentation
• Not include:
  o length of time on mechanical ventilation
  o the use of hypothermia
  o the size and location of ICH.
• The sample size
  o adequate in establishing significant associations between
    the exposures and outcomes,
  o not large enough to avoid fairly broad CIs.


                                                                17
Conclusion
Increased risk of the development of
pneumonia in patients with sICH:

• Mechanical ventilation, tube feeding, dysphagia, and
  tracheostomy
• Independently associated with pneumonia, even when
  potentially confounding variables are considered: GCS &
  mRS on admission and the use of PPI / H2 blockers, ACE-I.


Pneumonia in patients with sICH 

• Increased morbidity, hospital length of stay, and mortality

Need for increased vigilance & scrupulous
adherence to intensive care protocols

• designed to reduce the occurrence of pneumonia in
  patients with sICH.
                                                                18
Education of health care personnel


                    Active surveillance of VAP


                Minimizing the duration of ventilation


               Adherence to hand hygiene guidelines


         Maintaining patients in a semi-recumbent position


                          Good oral care

The use of strategies to decrease the contamination of equipments
        used for care in patients on mechancal ventilation.

                                                                19
Critical Appraisal




                     20
21
Research Question
               1                             2
P Patients with sICH         Patients with sICH
I MV, tracheostomy,          Pneumonia
  tube feeding, dysphagia
C -                          -
O Increase risk of           Increase in
  development of             morbidity, mortality, length
  pneumonia                  of stay
                         Prognosis

               Study design: Retrospective
                                                            22
Hierarchy of study designs




                             23
Case-Control


                                                 Odds diseased
 Factor =                                        Exposed to factor
   early            37                           = (37/18)
  infant
 formula
                                 50
                                                 Odds diseased
                    13                           Unexposed to factor
 Disease =                                       = (13/32)
Early onset
     of
  asthma            18



                                      50         Odds Ratio (OR)
                    32                           =
                                                 (37/18)
                                Present Time
                                                 (13/32)
                                                 = 5,1
                                      Starting
                                       point



              Past Time



                                                                       25
Cohort Study

                                                               100


                                       300
                                                               200

               1000
                                                                50
   Factor =           Disease =
     early           Early onset
    infant
   formula
                          of
                       asthma
                                       700
                                                                650
Present Time                                                         Past Time
    Starting




                                                          Relative Risk =
     point




               Incidence diseased   Incidence diseased
               Exposed to factor    Unexposed to factor   (100/300) = 4,7
               = (100/300)          = (50/700)            (50/700)


                                                                                 26
Validity
Recruitment -- “Were the subjects representative?”
Patients should ideally be enrolled at a   sICH at 24-h onset
uniformly early time in the disease
Patients should also be representative     Demographic data
of the underlying population.
Patients from tertiary referral centres    Single-center, type?
may have more advanced disease
and poorer prognoses than patients
from primary care.

Adjustment — “If subgroups with different prognoses are identified, did
adjustment for important prognostic factors take place?”
Adjust for known prognostic factors in     Multivariate analysis
the analysis so that the result indicate
the additional prognostic information.
Maintenance --“Was the comparable status of the study groups maintained
through equal management? Adequate follow-up?””
Prognosis is always conditional on        Equal?
treatment,  initial and subsequent       Protocol to treat pneumonia
treatment should be clearly spelt out,    Limitation in ICH therapy
Follow-up should be long enough to        All px: Discharge or death
detect the outcome of interest            Reasons for loss to follow-up?


Measurement: “Were the subjects and assessors kept „blind‟ to which treatment
was being received and/or were the measures objective ?”
Ideal if both the outcome assessors and   Outcome: dx pneumonia criteria,
the subjects are blinded to the nature    mortality, mRS, LoS
of the study groups.
If the outcome is objective (eg death)
then blinding is less critical.
If the outcome is subjective (eg
symptoms or function) then blinding of
the outcome assessor is critical.




                                                                                28
Importance
• OR, ORa  clinical significance (+)
• Statistical significance  available p-value
Applicability
• Study population similar to our own
• Results will lead to therapy selection
• Results useful for counseling patient or family
End
Thank You




            31

More Related Content

What's hot

Monitoring hemodinamik invasif
Monitoring hemodinamik invasifMonitoring hemodinamik invasif
Monitoring hemodinamik invasif
Nur Hajriya
 
Eracs fix
Eracs fixEracs fix
Kodeki tahun-2012
Kodeki tahun-2012Kodeki tahun-2012
Kodeki tahun-2012
budhi mp
 
Mencegah VAP ( Ventilator Associated Pneumonia )
Mencegah VAP ( Ventilator Associated Pneumonia )Mencegah VAP ( Ventilator Associated Pneumonia )
Mencegah VAP ( Ventilator Associated Pneumonia )
Bambang Fadhil
 
Referat pneumothorax
Referat pneumothoraxReferat pneumothorax
Referat pneumothoraxListiana Dewi
 
3. lensa
3. lensa3. lensa
3. lensa
fikri asyura
 
08 persalinan preterm
08 persalinan preterm08 persalinan preterm
08 persalinan pretermJoni Iswanto
 
Nutrisi ppok
Nutrisi ppokNutrisi ppok
Nutrisi ppok
su darto
 
Ventilasi Mekanik (Mechanical Ventilator) Eri Yanuar
Ventilasi Mekanik (Mechanical Ventilator) Eri YanuarVentilasi Mekanik (Mechanical Ventilator) Eri Yanuar
Ventilasi Mekanik (Mechanical Ventilator) Eri Yanuar
Eri Yanuar Akhmad B Sunaryo
 
TEMPORARY PACE MAKER
TEMPORARY PACE MAKERTEMPORARY PACE MAKER
TEMPORARY PACE MAKER
ari purwahyudi nugroho
 
Hematothorax
HematothoraxHematothorax
Hematothorax
ssuserba0713
 
Klasifikasi stadium klinis hiv aids menurut who
Klasifikasi stadium klinis hiv aids menurut whoKlasifikasi stadium klinis hiv aids menurut who
Klasifikasi stadium klinis hiv aids menurut who
Operator Warnet Vast Raha
 
Laporan Kasus Stroke Hemoragik
Laporan Kasus Stroke HemoragikLaporan Kasus Stroke Hemoragik
Laporan Kasus Stroke Hemoragik
Aulia Amani
 
06 partograf
06 partograf06 partograf
06 partograf
Joni Iswanto
 
Pedoman Nasiaonal Penyakit TB 2014
Pedoman Nasiaonal Penyakit TB 2014Pedoman Nasiaonal Penyakit TB 2014
Pedoman Nasiaonal Penyakit TB 2014
Dokter Tekno
 
Referat asfiksia neonatorum desi pupu final
Referat asfiksia neonatorum desi pupu finalReferat asfiksia neonatorum desi pupu final
Referat asfiksia neonatorum desi pupu finalSuzika Dewi
 
Edema paru
Edema paruEdema paru
Edema paru
Nathania Longkutoy
 
Ppt jurnal reading mata
Ppt jurnal reading mataPpt jurnal reading mata
Ppt jurnal reading mata
Ecye Tuhusula
 
Manajemen sumbatan jalan napas
Manajemen sumbatan jalan napasManajemen sumbatan jalan napas
Manajemen sumbatan jalan napas
Feri TheEase
 

What's hot (20)

BPH ppt
BPH pptBPH ppt
BPH ppt
 
Monitoring hemodinamik invasif
Monitoring hemodinamik invasifMonitoring hemodinamik invasif
Monitoring hemodinamik invasif
 
Eracs fix
Eracs fixEracs fix
Eracs fix
 
Kodeki tahun-2012
Kodeki tahun-2012Kodeki tahun-2012
Kodeki tahun-2012
 
Mencegah VAP ( Ventilator Associated Pneumonia )
Mencegah VAP ( Ventilator Associated Pneumonia )Mencegah VAP ( Ventilator Associated Pneumonia )
Mencegah VAP ( Ventilator Associated Pneumonia )
 
Referat pneumothorax
Referat pneumothoraxReferat pneumothorax
Referat pneumothorax
 
3. lensa
3. lensa3. lensa
3. lensa
 
08 persalinan preterm
08 persalinan preterm08 persalinan preterm
08 persalinan preterm
 
Nutrisi ppok
Nutrisi ppokNutrisi ppok
Nutrisi ppok
 
Ventilasi Mekanik (Mechanical Ventilator) Eri Yanuar
Ventilasi Mekanik (Mechanical Ventilator) Eri YanuarVentilasi Mekanik (Mechanical Ventilator) Eri Yanuar
Ventilasi Mekanik (Mechanical Ventilator) Eri Yanuar
 
TEMPORARY PACE MAKER
TEMPORARY PACE MAKERTEMPORARY PACE MAKER
TEMPORARY PACE MAKER
 
Hematothorax
HematothoraxHematothorax
Hematothorax
 
Klasifikasi stadium klinis hiv aids menurut who
Klasifikasi stadium klinis hiv aids menurut whoKlasifikasi stadium klinis hiv aids menurut who
Klasifikasi stadium klinis hiv aids menurut who
 
Laporan Kasus Stroke Hemoragik
Laporan Kasus Stroke HemoragikLaporan Kasus Stroke Hemoragik
Laporan Kasus Stroke Hemoragik
 
06 partograf
06 partograf06 partograf
06 partograf
 
Pedoman Nasiaonal Penyakit TB 2014
Pedoman Nasiaonal Penyakit TB 2014Pedoman Nasiaonal Penyakit TB 2014
Pedoman Nasiaonal Penyakit TB 2014
 
Referat asfiksia neonatorum desi pupu final
Referat asfiksia neonatorum desi pupu finalReferat asfiksia neonatorum desi pupu final
Referat asfiksia neonatorum desi pupu final
 
Edema paru
Edema paruEdema paru
Edema paru
 
Ppt jurnal reading mata
Ppt jurnal reading mataPpt jurnal reading mata
Ppt jurnal reading mata
 
Manajemen sumbatan jalan napas
Manajemen sumbatan jalan napasManajemen sumbatan jalan napas
Manajemen sumbatan jalan napas
 

Similar to ICH & pneumonia

HAP-VAP Seminar.pptx
HAP-VAP Seminar.pptxHAP-VAP Seminar.pptx
HAP-VAP Seminar.pptx
AbdirizakJacda
 
Hap
HapHap
Nosocomial infections
Nosocomial infectionsNosocomial infections
Nosocomial infections
anaesthesiaESICMCH
 
fever in the postoperative period .ppt
fever in the postoperative period .pptfever in the postoperative period .ppt
fever in the postoperative period .ppt
SinzianaIonescu1
 
Aspiration pneumonia
Aspiration pneumoniaAspiration pneumonia
Aspiration pneumonia
Diptiman Behera
 
Sepsis and antibiotic guidance in neurology wards
Sepsis and antibiotic guidance in neurology wardsSepsis and antibiotic guidance in neurology wards
Sepsis and antibiotic guidance in neurology wards
Divya Shilpa
 
hospital-acquired and ventilator-associated pneumonia
hospital-acquired and ventilator-associated pneumonia hospital-acquired and ventilator-associated pneumonia
hospital-acquired and ventilator-associated pneumonia
Mohammed Al-Mashaqba
 
PATTERN OF HOSPITAL-ACQUIRED PNEUMONIA IN INTENSIVE CARE UNIT OF SUEZ CANAL U...
PATTERN OF HOSPITAL-ACQUIRED PNEUMONIA IN INTENSIVE CARE UNIT OF SUEZ CANAL U...PATTERN OF HOSPITAL-ACQUIRED PNEUMONIA IN INTENSIVE CARE UNIT OF SUEZ CANAL U...
PATTERN OF HOSPITAL-ACQUIRED PNEUMONIA IN INTENSIVE CARE UNIT OF SUEZ CANAL U...
Khaled Mohamed
 
Epidemiology treatment and_outcomes_of_sa_nosocomial_pneumonia_chest_2005-1
Epidemiology treatment and_outcomes_of_sa_nosocomial_pneumonia_chest_2005-1Epidemiology treatment and_outcomes_of_sa_nosocomial_pneumonia_chest_2005-1
Epidemiology treatment and_outcomes_of_sa_nosocomial_pneumonia_chest_2005-1
Christian Wilhelm
 
Non resolving pneumonia
Non resolving pneumoniaNon resolving pneumonia
Non resolving pneumonia
Sayantan Saha
 
Antibiotic Strategy in Lower Respiratory Tract Infections (part 2)
Antibiotic Strategy in Lower Respiratory Tract Infections (part 2)Antibiotic Strategy in Lower Respiratory Tract Infections (part 2)
Antibiotic Strategy in Lower Respiratory Tract Infections (part 2)
Gamal Agmy
 
Ventilator Associated Pneumonia Management.pptx
Ventilator Associated Pneumonia Management.pptxVentilator Associated Pneumonia Management.pptx
Ventilator Associated Pneumonia Management.pptx
DileepRedemption
 
Community acquired pneumonia (cap)
Community   acquired pneumonia (cap)Community   acquired pneumonia (cap)
Community acquired pneumonia (cap)
Ngọc Anh Lương
 
Ventilator associated pneumonia in the icu
Ventilator associated pneumonia in the icuVentilator associated pneumonia in the icu
Ventilator associated pneumonia in the icu
Chamika Huruggamuwa
 
Management Of Community Acquired Pneumonia
Management  Of Community Acquired PneumoniaManagement  Of Community Acquired Pneumonia
Management Of Community Acquired Pneumonia
Ashraf ElAdawy
 
CAP.ppt
CAP.pptCAP.ppt
Ventilator associated pneumonia (1).pptx
Ventilator associated pneumonia (1).pptxVentilator associated pneumonia (1).pptx
Ventilator associated pneumonia (1).pptx
rekha reddy
 
Pneumonia management guidelines
Pneumonia management guidelinesPneumonia management guidelines
Pneumonia management guidelines
Mehakinder Singh
 
VENTILATOR ACQUIRED PNEUMONIUA.pptx
VENTILATOR ACQUIRED PNEUMONIUA.pptxVENTILATOR ACQUIRED PNEUMONIUA.pptx
VENTILATOR ACQUIRED PNEUMONIUA.pptx
TolaOjo1
 
Ventilator associated infections VAP
Ventilator associated infections VAP Ventilator associated infections VAP
Ventilator associated infections VAP
Thair Abuaqeel
 

Similar to ICH & pneumonia (20)

HAP-VAP Seminar.pptx
HAP-VAP Seminar.pptxHAP-VAP Seminar.pptx
HAP-VAP Seminar.pptx
 
Hap
HapHap
Hap
 
Nosocomial infections
Nosocomial infectionsNosocomial infections
Nosocomial infections
 
fever in the postoperative period .ppt
fever in the postoperative period .pptfever in the postoperative period .ppt
fever in the postoperative period .ppt
 
Aspiration pneumonia
Aspiration pneumoniaAspiration pneumonia
Aspiration pneumonia
 
Sepsis and antibiotic guidance in neurology wards
Sepsis and antibiotic guidance in neurology wardsSepsis and antibiotic guidance in neurology wards
Sepsis and antibiotic guidance in neurology wards
 
hospital-acquired and ventilator-associated pneumonia
hospital-acquired and ventilator-associated pneumonia hospital-acquired and ventilator-associated pneumonia
hospital-acquired and ventilator-associated pneumonia
 
PATTERN OF HOSPITAL-ACQUIRED PNEUMONIA IN INTENSIVE CARE UNIT OF SUEZ CANAL U...
PATTERN OF HOSPITAL-ACQUIRED PNEUMONIA IN INTENSIVE CARE UNIT OF SUEZ CANAL U...PATTERN OF HOSPITAL-ACQUIRED PNEUMONIA IN INTENSIVE CARE UNIT OF SUEZ CANAL U...
PATTERN OF HOSPITAL-ACQUIRED PNEUMONIA IN INTENSIVE CARE UNIT OF SUEZ CANAL U...
 
Epidemiology treatment and_outcomes_of_sa_nosocomial_pneumonia_chest_2005-1
Epidemiology treatment and_outcomes_of_sa_nosocomial_pneumonia_chest_2005-1Epidemiology treatment and_outcomes_of_sa_nosocomial_pneumonia_chest_2005-1
Epidemiology treatment and_outcomes_of_sa_nosocomial_pneumonia_chest_2005-1
 
Non resolving pneumonia
Non resolving pneumoniaNon resolving pneumonia
Non resolving pneumonia
 
Antibiotic Strategy in Lower Respiratory Tract Infections (part 2)
Antibiotic Strategy in Lower Respiratory Tract Infections (part 2)Antibiotic Strategy in Lower Respiratory Tract Infections (part 2)
Antibiotic Strategy in Lower Respiratory Tract Infections (part 2)
 
Ventilator Associated Pneumonia Management.pptx
Ventilator Associated Pneumonia Management.pptxVentilator Associated Pneumonia Management.pptx
Ventilator Associated Pneumonia Management.pptx
 
Community acquired pneumonia (cap)
Community   acquired pneumonia (cap)Community   acquired pneumonia (cap)
Community acquired pneumonia (cap)
 
Ventilator associated pneumonia in the icu
Ventilator associated pneumonia in the icuVentilator associated pneumonia in the icu
Ventilator associated pneumonia in the icu
 
Management Of Community Acquired Pneumonia
Management  Of Community Acquired PneumoniaManagement  Of Community Acquired Pneumonia
Management Of Community Acquired Pneumonia
 
CAP.ppt
CAP.pptCAP.ppt
CAP.ppt
 
Ventilator associated pneumonia (1).pptx
Ventilator associated pneumonia (1).pptxVentilator associated pneumonia (1).pptx
Ventilator associated pneumonia (1).pptx
 
Pneumonia management guidelines
Pneumonia management guidelinesPneumonia management guidelines
Pneumonia management guidelines
 
VENTILATOR ACQUIRED PNEUMONIUA.pptx
VENTILATOR ACQUIRED PNEUMONIUA.pptxVENTILATOR ACQUIRED PNEUMONIUA.pptx
VENTILATOR ACQUIRED PNEUMONIUA.pptx
 
Ventilator associated infections VAP
Ventilator associated infections VAP Ventilator associated infections VAP
Ventilator associated infections VAP
 

More from Ersifa Fatimah

Choosing the right antiseizure medication for epilepsy
Choosing the right antiseizure medication for epilepsy  Choosing the right antiseizure medication for epilepsy
Choosing the right antiseizure medication for epilepsy
Ersifa Fatimah
 
The Definition of Drug Resistant Epilepsy
The Definition of Drug Resistant EpilepsyThe Definition of Drug Resistant Epilepsy
The Definition of Drug Resistant Epilepsy
Ersifa Fatimah
 
Seizure Semiology: Introduction
Seizure Semiology: IntroductionSeizure Semiology: Introduction
Seizure Semiology: Introduction
Ersifa Fatimah
 
The Philosophy of EEG Interpretation
The Philosophy of EEG Interpretation The Philosophy of EEG Interpretation
The Philosophy of EEG Interpretation
Ersifa Fatimah
 
Meningoensefalitis: minireview
Meningoensefalitis: minireviewMeningoensefalitis: minireview
Meningoensefalitis: minireview
Ersifa Fatimah
 
Stroke Hemodinamik
Stroke HemodinamikStroke Hemodinamik
Stroke Hemodinamik
Ersifa Fatimah
 
Small vessel disease: Evolving concept
Small vessel disease: Evolving conceptSmall vessel disease: Evolving concept
Small vessel disease: Evolving concept
Ersifa Fatimah
 
How low can you go?
How low can you go?How low can you go?
How low can you go?
Ersifa Fatimah
 
Effect of Blood Pressure Lowering in Early Ischemic Stroke, Time to Change Pr...
Effect of Blood Pressure Lowering in Early Ischemic Stroke, Time to Change Pr...Effect of Blood Pressure Lowering in Early Ischemic Stroke, Time to Change Pr...
Effect of Blood Pressure Lowering in Early Ischemic Stroke, Time to Change Pr...
Ersifa Fatimah
 
Ischemic Stroke Subclassification, An Asian Viewpoint
Ischemic Stroke Subclassification, An Asian ViewpointIschemic Stroke Subclassification, An Asian Viewpoint
Ischemic Stroke Subclassification, An Asian Viewpoint
Ersifa Fatimah
 
EKOLOGI KESEHATAN
EKOLOGI KESEHATANEKOLOGI KESEHATAN
EKOLOGI KESEHATAN
Ersifa Fatimah
 
World Stroke Day 2015 : I am Woman
World Stroke Day 2015 : I am WomanWorld Stroke Day 2015 : I am Woman
World Stroke Day 2015 : I am Woman
Ersifa Fatimah
 
PHASES aneurysm rupture risk score
PHASES aneurysm rupture risk scorePHASES aneurysm rupture risk score
PHASES aneurysm rupture risk score
Ersifa Fatimah
 
Terapi Endovaskuler, Standar Baru Manajemen Stroke Iskemik Akut?
Terapi Endovaskuler, Standar Baru Manajemen Stroke Iskemik Akut? Terapi Endovaskuler, Standar Baru Manajemen Stroke Iskemik Akut?
Terapi Endovaskuler, Standar Baru Manajemen Stroke Iskemik Akut?
Ersifa Fatimah
 
Parkinsonism Puzzle
Parkinsonism PuzzleParkinsonism Puzzle
Parkinsonism Puzzle
Ersifa Fatimah
 
aSAH - coil vs clip
aSAH - coil vs clipaSAH - coil vs clip
aSAH - coil vs clip
Ersifa Fatimah
 
Microsurgery for cerebral AVM, Theofanis et al, Neurosurg Focus, 2014
Microsurgery for cerebral AVM, Theofanis et al, Neurosurg Focus, 2014Microsurgery for cerebral AVM, Theofanis et al, Neurosurg Focus, 2014
Microsurgery for cerebral AVM, Theofanis et al, Neurosurg Focus, 2014
Ersifa Fatimah
 
Stroke prevention for nonvalvular AF, summary of evidence-based guidelines
Stroke prevention for nonvalvular AF, summary of evidence-based guidelinesStroke prevention for nonvalvular AF, summary of evidence-based guidelines
Stroke prevention for nonvalvular AF, summary of evidence-based guidelines
Ersifa Fatimah
 
Ramadhan diary
Ramadhan diaryRamadhan diary
Ramadhan diary
Ersifa Fatimah
 
HINTS of Stroke, Bedside Eye Exam Outperforms MRI in Identifying Stroke
HINTS of Stroke, Bedside Eye Exam Outperforms MRI in Identifying StrokeHINTS of Stroke, Bedside Eye Exam Outperforms MRI in Identifying Stroke
HINTS of Stroke, Bedside Eye Exam Outperforms MRI in Identifying Stroke
Ersifa Fatimah
 

More from Ersifa Fatimah (20)

Choosing the right antiseizure medication for epilepsy
Choosing the right antiseizure medication for epilepsy  Choosing the right antiseizure medication for epilepsy
Choosing the right antiseizure medication for epilepsy
 
The Definition of Drug Resistant Epilepsy
The Definition of Drug Resistant EpilepsyThe Definition of Drug Resistant Epilepsy
The Definition of Drug Resistant Epilepsy
 
Seizure Semiology: Introduction
Seizure Semiology: IntroductionSeizure Semiology: Introduction
Seizure Semiology: Introduction
 
The Philosophy of EEG Interpretation
The Philosophy of EEG Interpretation The Philosophy of EEG Interpretation
The Philosophy of EEG Interpretation
 
Meningoensefalitis: minireview
Meningoensefalitis: minireviewMeningoensefalitis: minireview
Meningoensefalitis: minireview
 
Stroke Hemodinamik
Stroke HemodinamikStroke Hemodinamik
Stroke Hemodinamik
 
Small vessel disease: Evolving concept
Small vessel disease: Evolving conceptSmall vessel disease: Evolving concept
Small vessel disease: Evolving concept
 
How low can you go?
How low can you go?How low can you go?
How low can you go?
 
Effect of Blood Pressure Lowering in Early Ischemic Stroke, Time to Change Pr...
Effect of Blood Pressure Lowering in Early Ischemic Stroke, Time to Change Pr...Effect of Blood Pressure Lowering in Early Ischemic Stroke, Time to Change Pr...
Effect of Blood Pressure Lowering in Early Ischemic Stroke, Time to Change Pr...
 
Ischemic Stroke Subclassification, An Asian Viewpoint
Ischemic Stroke Subclassification, An Asian ViewpointIschemic Stroke Subclassification, An Asian Viewpoint
Ischemic Stroke Subclassification, An Asian Viewpoint
 
EKOLOGI KESEHATAN
EKOLOGI KESEHATANEKOLOGI KESEHATAN
EKOLOGI KESEHATAN
 
World Stroke Day 2015 : I am Woman
World Stroke Day 2015 : I am WomanWorld Stroke Day 2015 : I am Woman
World Stroke Day 2015 : I am Woman
 
PHASES aneurysm rupture risk score
PHASES aneurysm rupture risk scorePHASES aneurysm rupture risk score
PHASES aneurysm rupture risk score
 
Terapi Endovaskuler, Standar Baru Manajemen Stroke Iskemik Akut?
Terapi Endovaskuler, Standar Baru Manajemen Stroke Iskemik Akut? Terapi Endovaskuler, Standar Baru Manajemen Stroke Iskemik Akut?
Terapi Endovaskuler, Standar Baru Manajemen Stroke Iskemik Akut?
 
Parkinsonism Puzzle
Parkinsonism PuzzleParkinsonism Puzzle
Parkinsonism Puzzle
 
aSAH - coil vs clip
aSAH - coil vs clipaSAH - coil vs clip
aSAH - coil vs clip
 
Microsurgery for cerebral AVM, Theofanis et al, Neurosurg Focus, 2014
Microsurgery for cerebral AVM, Theofanis et al, Neurosurg Focus, 2014Microsurgery for cerebral AVM, Theofanis et al, Neurosurg Focus, 2014
Microsurgery for cerebral AVM, Theofanis et al, Neurosurg Focus, 2014
 
Stroke prevention for nonvalvular AF, summary of evidence-based guidelines
Stroke prevention for nonvalvular AF, summary of evidence-based guidelinesStroke prevention for nonvalvular AF, summary of evidence-based guidelines
Stroke prevention for nonvalvular AF, summary of evidence-based guidelines
 
Ramadhan diary
Ramadhan diaryRamadhan diary
Ramadhan diary
 
HINTS of Stroke, Bedside Eye Exam Outperforms MRI in Identifying Stroke
HINTS of Stroke, Bedside Eye Exam Outperforms MRI in Identifying StrokeHINTS of Stroke, Bedside Eye Exam Outperforms MRI in Identifying Stroke
HINTS of Stroke, Bedside Eye Exam Outperforms MRI in Identifying Stroke
 

Recently uploaded

Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotesPromoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
PsychoTech Services
 
Efficacy of Avartana Sneha in Ayurveda
Efficacy of Avartana Sneha in AyurvedaEfficacy of Avartana Sneha in Ayurveda
Efficacy of Avartana Sneha in Ayurveda
Dr. Jyothirmai Paindla
 
Abortion PG Seminar Power point presentation
Abortion PG Seminar Power point presentationAbortion PG Seminar Power point presentation
Abortion PG Seminar Power point presentation
AksshayaRajanbabu
 
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
Holistified Wellness
 
DECLARATION OF HELSINKI - History and principles
DECLARATION OF HELSINKI - History and principlesDECLARATION OF HELSINKI - History and principles
DECLARATION OF HELSINKI - History and principles
anaghabharat01
 
share - Lions, tigers, AI and health misinformation, oh my!.pptx
share - Lions, tigers, AI and health misinformation, oh my!.pptxshare - Lions, tigers, AI and health misinformation, oh my!.pptx
share - Lions, tigers, AI and health misinformation, oh my!.pptx
Tina Purnat
 
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdfCHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
rishi2789
 
Chapter 11 Nutrition and Chronic Diseases.pptx
Chapter 11 Nutrition and Chronic Diseases.pptxChapter 11 Nutrition and Chronic Diseases.pptx
Chapter 11 Nutrition and Chronic Diseases.pptx
Earlene McNair
 
Travel Clinic Cardiff: Health Advice for International Travelers
Travel Clinic Cardiff: Health Advice for International TravelersTravel Clinic Cardiff: Health Advice for International Travelers
Travel Clinic Cardiff: Health Advice for International Travelers
NX Healthcare
 
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptxREGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
LaniyaNasrink
 
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.GawadHemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
NephroTube - Dr.Gawad
 
Adhd Medication Shortage Uk - trinexpharmacy.com
Adhd Medication Shortage Uk - trinexpharmacy.comAdhd Medication Shortage Uk - trinexpharmacy.com
Adhd Medication Shortage Uk - trinexpharmacy.com
reignlana06
 
Cosmetology and Trichology Courses at Kosmoderma Academy PRP (Hair), DR Growt...
Cosmetology and Trichology Courses at Kosmoderma Academy PRP (Hair), DR Growt...Cosmetology and Trichology Courses at Kosmoderma Academy PRP (Hair), DR Growt...
Cosmetology and Trichology Courses at Kosmoderma Academy PRP (Hair), DR Growt...
Kosmoderma Academy Of Aesthetic Medicine
 
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
rishi2789
 
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptx
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptxMuscles of Mastication by Dr. Rabia Inam Gandapore.pptx
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptx
Dr. Rabia Inam Gandapore
 
Pharmacology of 5-hydroxytryptamine and Antagonist
Pharmacology of 5-hydroxytryptamine and AntagonistPharmacology of 5-hydroxytryptamine and Antagonist
Pharmacology of 5-hydroxytryptamine and Antagonist
Dr. Nikhilkumar Sakle
 
CLEAR ALIGNER THERAPY IN ORTHODONTICS .pptx
CLEAR ALIGNER THERAPY IN ORTHODONTICS .pptxCLEAR ALIGNER THERAPY IN ORTHODONTICS .pptx
CLEAR ALIGNER THERAPY IN ORTHODONTICS .pptx
Government Dental College & Hospital Srinagar
 
Complementary feeding in infant IAP PROTOCOLS
Complementary feeding in infant IAP PROTOCOLSComplementary feeding in infant IAP PROTOCOLS
Complementary feeding in infant IAP PROTOCOLS
chiranthgowda16
 
pathology MCQS introduction to pathology general pathology
pathology MCQS introduction to pathology general pathologypathology MCQS introduction to pathology general pathology
pathology MCQS introduction to pathology general pathology
ZayedKhan38
 
Physical demands in sports - WCSPT Oslo 2024
Physical demands in sports - WCSPT Oslo 2024Physical demands in sports - WCSPT Oslo 2024
Physical demands in sports - WCSPT Oslo 2024
Torstein Dalen-Lorentsen
 

Recently uploaded (20)

Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotesPromoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
 
Efficacy of Avartana Sneha in Ayurveda
Efficacy of Avartana Sneha in AyurvedaEfficacy of Avartana Sneha in Ayurveda
Efficacy of Avartana Sneha in Ayurveda
 
Abortion PG Seminar Power point presentation
Abortion PG Seminar Power point presentationAbortion PG Seminar Power point presentation
Abortion PG Seminar Power point presentation
 
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
 
DECLARATION OF HELSINKI - History and principles
DECLARATION OF HELSINKI - History and principlesDECLARATION OF HELSINKI - History and principles
DECLARATION OF HELSINKI - History and principles
 
share - Lions, tigers, AI and health misinformation, oh my!.pptx
share - Lions, tigers, AI and health misinformation, oh my!.pptxshare - Lions, tigers, AI and health misinformation, oh my!.pptx
share - Lions, tigers, AI and health misinformation, oh my!.pptx
 
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdfCHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
 
Chapter 11 Nutrition and Chronic Diseases.pptx
Chapter 11 Nutrition and Chronic Diseases.pptxChapter 11 Nutrition and Chronic Diseases.pptx
Chapter 11 Nutrition and Chronic Diseases.pptx
 
Travel Clinic Cardiff: Health Advice for International Travelers
Travel Clinic Cardiff: Health Advice for International TravelersTravel Clinic Cardiff: Health Advice for International Travelers
Travel Clinic Cardiff: Health Advice for International Travelers
 
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptxREGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
 
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.GawadHemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
 
Adhd Medication Shortage Uk - trinexpharmacy.com
Adhd Medication Shortage Uk - trinexpharmacy.comAdhd Medication Shortage Uk - trinexpharmacy.com
Adhd Medication Shortage Uk - trinexpharmacy.com
 
Cosmetology and Trichology Courses at Kosmoderma Academy PRP (Hair), DR Growt...
Cosmetology and Trichology Courses at Kosmoderma Academy PRP (Hair), DR Growt...Cosmetology and Trichology Courses at Kosmoderma Academy PRP (Hair), DR Growt...
Cosmetology and Trichology Courses at Kosmoderma Academy PRP (Hair), DR Growt...
 
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
 
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptx
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptxMuscles of Mastication by Dr. Rabia Inam Gandapore.pptx
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptx
 
Pharmacology of 5-hydroxytryptamine and Antagonist
Pharmacology of 5-hydroxytryptamine and AntagonistPharmacology of 5-hydroxytryptamine and Antagonist
Pharmacology of 5-hydroxytryptamine and Antagonist
 
CLEAR ALIGNER THERAPY IN ORTHODONTICS .pptx
CLEAR ALIGNER THERAPY IN ORTHODONTICS .pptxCLEAR ALIGNER THERAPY IN ORTHODONTICS .pptx
CLEAR ALIGNER THERAPY IN ORTHODONTICS .pptx
 
Complementary feeding in infant IAP PROTOCOLS
Complementary feeding in infant IAP PROTOCOLSComplementary feeding in infant IAP PROTOCOLS
Complementary feeding in infant IAP PROTOCOLS
 
pathology MCQS introduction to pathology general pathology
pathology MCQS introduction to pathology general pathologypathology MCQS introduction to pathology general pathology
pathology MCQS introduction to pathology general pathology
 
Physical demands in sports - WCSPT Oslo 2024
Physical demands in sports - WCSPT Oslo 2024Physical demands in sports - WCSPT Oslo 2024
Physical demands in sports - WCSPT Oslo 2024
 

ICH & pneumonia

  • 1. Predictors and Outcomes of Pneumonia in Patients With Spontaneous Intracerebral Hemorrhage Alsumrain M, et al J Intensive Care Med February 14, 2012 Journal Reading Ersifa Fatimah, dr. Pembimbing: dr. Hendro Susilo, SpS(K) Pengamat: dr. Yudha Haryono, SpS
  • 2. Introduction ICH, common form of stroke  1/5 of all cases Respiratory tract infection in ICU 30-60% of all infection Pneumonia have the highest mortality rate among all medical complications after stroke To predict which patients will benefit from early & more aggressive treatment There is little data on the incidence of pneumonia in patients with ICH / neuro-ICU 2
  • 3. Objectives To determine the predictors and outcomes of the development of pneumonia in patients with sICH. 3
  • 4. Methods 290 consecutive patients with sICH admitted within 24 hours of stroke onset, at New Jersey Neuroscience Institute - J F Kennedy Hospital, from January 2006 to July 2009 Data Demographic data GCS & mRS Pneumonia & exposure Additional data Site & type pneumonia, LoS, PPI, H2B, ACE-I, smoking, alcohol Statistical analysis 4
  • 5. Definitions Pneumonia • Dx: 2007 consensus guidelines from the Infectious Diseases Society of America & the American Thoracic Society • Include: a constellation of suggestive clinical features, a demonstrable infiltrate by chest radiograph or other imaging technique, with / without supporting microbiological data. Ventilator-associated pneumonia (VAP) • Exposure to MV at any point during hospital course • Px developed pneumonia after 48 hours on the ventilator • Uses VAP bundle according to the Joint Commission on Accreditation of Healthcare Organizations for the prevention of pneumonia in mechanically ventilated patients. Dysphagia • diagnosed after a standardized speech and swallow evaluation completed by a team of speech therapist. Tube feeding • Started within 48 hours of hospitalization. 5
  • 6. Results & Discussion • 290 patients (-10?) • 159 (56.5%) male • mean age of 66.6 years (SD +/- 16.2). • 13.93% patients developed pneumonia. 6
  • 7. Cont. • Patients who developed pneumonia had a lower GCS (mean = 9.1) & higher mRS (mean = 4) on admission. Those without pneumonia, the mean of GCS = 12.6 & mRS = 2.77 Substantial risk of pneumonia is associated with (each of these parameters, cut offs): mRS 2.5 (=< 2 vs =>3) ORa 5.18 (2.10 – 12.8) GCS 13.5 (=<13 vs =>14) ORa 6.27 (2.84 – 13.9) 7
  • 8. PPI , H2-blockers and Pneumonia Normal gastric juice with a pH below 4  most pathogens are killed • Suppression of gastric acid  no defense from bacteria multiplying  colonization of pathogens, particularly gram- positive bacteria, from the upper GIT • Aspiration is important mechanism in the development of nosocomial pneumonia. Degree of bacterial overgrowth depends on the degree of reduction in gastric acid secretion • Bacterial overgrowth is considerably higher in patients treated with PPI compared with H2-receptor antagonist. 8
  • 9. ACE inhibitors & Pneumonia Our study Other studies The use of ACE-I predisposes those ACE-I beneficial for elderly patients with sICH to develop pneumonia with intracerebral hemorrhage or stroke, who are at risk of pneumonia. Protective effects of ACE-I • Attributed to an increase in substance P & bradykinin. ACE-I has different effects on racial populations: • Most of the studies involving ACE-I involve only Asian population. • Studies involving a general white population show no reduced hospitalization for community acquired pneumonia for patients using ACE-I. 9
  • 10. 93(33.2%)patients required mechanical ventilation at one point of their disease course  VAP 76%. • The most common site of pneumonia: the right lower lobe (41%). • The most common isolated organisms: Pseudomonas aeruginosa & Klebsiella pneumoniae, from 12 patients (30.7%) with pneumonia Univariate analysis: Variables & OR (95% CI) Mechanical ventilation 9.42 (4.24 - 20.9) Tube feeding 22.3 (8.91 – 55.8) Dysphagia 13.1 (4.66 – 36.7) Tracheostomy 26.8 (8.02 – 89.3) 10
  • 11. Multivariate analysis • Relatively small differences in ORa after adjusting for potential confounders • Most interaction terms were not significant • Exception: o H2-blockers for MV o GCS & mRS for all but dysphagia & MV [only GCS yielded a significant interaction]. All potential confounders left the 4 primary exposures statistically significant after adjustment. 11
  • 12. • Primary route of bacterial entry into the trachea: • aspiration of oropharyngeal pathogens • leakage of bacteria around the endotracheal tube cuff. • Frequent need of MV in px with sICH  at a higher risk of pneumonia than any other group of patients. (in this study, 76.9% of patients who developed The minimum ORa was 3.72 (95% CI: 1.68 - 8.26) pneumonia were on when adjusted for GCS MV) 12
  • 13. The bronchial colonization of bacteria in upper airways during tracheostomy  reservoir for the lower airways colonization  increases risk of pneumonia. • Subsequent need for tracheostomy who required prolonged use of MV  with tracheostomy, incre ased risk of mRS reduced OR to 16.2 (95% CI: 4.98 - 52.8) ventilator- for tracheostomy associated tracheobronchitis ~ precursor for VAP. 13
  • 14. The mechanisms responsible: • desensitization of the pharyngo-glottal adduction reflex, • loss of anatomical integrity of the esophageal sphincters, • migration of gastric bacteria upward along the tube causing colonization of the pharynx. • Both GCS and mRS reduced ORa • GCS  to14.7(95% CI: 6.16-35.0) • mRS  to15.7(95% CI: 6.63-37.0). 14
  • 15. • Dysphagia is seen in 40 - 70% of patients who had an acute stroke  40 - 50% aspirate  increases the likelihood of developing pneumonia by 7-fold. mRS reduced OR to 7.46 (95% CI: 3.34 - 10.6) 15
  • 16. Effect of pneumonia on morbidity: • Increase in mRS between admission and discharge: o by 1.07(4-5.07) in patients with pneumonia o by 0.33 (2.77-3.1) in patients without pneumonia o P = .003 • The hospital length of stay: o The pneumonia group (mean = 19.56 days) o The no-pneumonia group (mean = 9.14 days), o P <.0001. • Mortality rate: o 10 (25.6%) patients died in pneumonia group o 30 (12%)patients died in no pneumonia group o P = .041 16
  • 17. Limitations • Retrospective protocol: o Some limitations, primarily due to existing documentation • Not include: o length of time on mechanical ventilation o the use of hypothermia o the size and location of ICH. • The sample size o adequate in establishing significant associations between the exposures and outcomes, o not large enough to avoid fairly broad CIs. 17
  • 18. Conclusion Increased risk of the development of pneumonia in patients with sICH: • Mechanical ventilation, tube feeding, dysphagia, and tracheostomy • Independently associated with pneumonia, even when potentially confounding variables are considered: GCS & mRS on admission and the use of PPI / H2 blockers, ACE-I. Pneumonia in patients with sICH  • Increased morbidity, hospital length of stay, and mortality Need for increased vigilance & scrupulous adherence to intensive care protocols • designed to reduce the occurrence of pneumonia in patients with sICH. 18
  • 19. Education of health care personnel Active surveillance of VAP Minimizing the duration of ventilation Adherence to hand hygiene guidelines Maintaining patients in a semi-recumbent position Good oral care The use of strategies to decrease the contamination of equipments used for care in patients on mechancal ventilation. 19
  • 21. 21
  • 22. Research Question 1 2 P Patients with sICH Patients with sICH I MV, tracheostomy, Pneumonia tube feeding, dysphagia C - - O Increase risk of Increase in development of morbidity, mortality, length pneumonia of stay Prognosis Study design: Retrospective 22
  • 23. Hierarchy of study designs 23
  • 24.
  • 25. Case-Control Odds diseased Factor = Exposed to factor early 37 = (37/18) infant formula 50 Odds diseased 13 Unexposed to factor Disease = = (13/32) Early onset of asthma 18 50 Odds Ratio (OR) 32 = (37/18) Present Time (13/32) = 5,1 Starting point Past Time 25
  • 26. Cohort Study 100 300 200 1000 50 Factor = Disease = early Early onset infant formula of asthma 700 650 Present Time Past Time Starting Relative Risk = point Incidence diseased Incidence diseased Exposed to factor Unexposed to factor (100/300) = 4,7 = (100/300) = (50/700) (50/700) 26
  • 27. Validity Recruitment -- “Were the subjects representative?” Patients should ideally be enrolled at a sICH at 24-h onset uniformly early time in the disease Patients should also be representative Demographic data of the underlying population. Patients from tertiary referral centres Single-center, type? may have more advanced disease and poorer prognoses than patients from primary care. Adjustment — “If subgroups with different prognoses are identified, did adjustment for important prognostic factors take place?” Adjust for known prognostic factors in Multivariate analysis the analysis so that the result indicate the additional prognostic information.
  • 28. Maintenance --“Was the comparable status of the study groups maintained through equal management? Adequate follow-up?”” Prognosis is always conditional on Equal? treatment,  initial and subsequent Protocol to treat pneumonia treatment should be clearly spelt out, Limitation in ICH therapy Follow-up should be long enough to All px: Discharge or death detect the outcome of interest Reasons for loss to follow-up? Measurement: “Were the subjects and assessors kept „blind‟ to which treatment was being received and/or were the measures objective ?” Ideal if both the outcome assessors and Outcome: dx pneumonia criteria, the subjects are blinded to the nature mortality, mRS, LoS of the study groups. If the outcome is objective (eg death) then blinding is less critical. If the outcome is subjective (eg symptoms or function) then blinding of the outcome assessor is critical. 28
  • 29. Importance • OR, ORa  clinical significance (+) • Statistical significance  available p-value
  • 30. Applicability • Study population similar to our own • Results will lead to therapy selection • Results useful for counseling patient or family

Editor's Notes

  1. Walopunadahubungansignifikanantaravariabel &amp; outcome, tpitubisadisebabkan/pengaruholeh confounder-nya